LAWRENCE, Mass., May 4, 2015 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading manufacturer of dialysis
products, today announced the Company's new Chronic Scientific
Advisory Board, an esteemed group of thought leaders focused on
evaluating and advancing home dialysis therapies. Senior
Medical Advisor, Dr. Allan J.
Collins, will lead the distinguished board of nephrologists
and cardio renal experts in actively defining, developing and
conducting strategic data analyses that promote the efficacy,
safety, and benefits of home hemodialysis (HHD) therapy with the
NxStage System One.
Board members and affiliations include:
- Allan Collins, MD - Senior
Medical Advisor of NxStage Medical, Inc.
- Chris Chan, MD – University
Health Network, Toronto,
Canada
- Michael A. Kraus, MD –
Indiana University School of Medicine,
Clarian Health
- Peter McCullough, MD –
Baylor University Medical Center
- Jose Morfin, MD – UC Davis
School of Medicine
- John Burkart, MD – Wake Forest University Medical Center
- Mike Copland, MD – University of British Columbia, Vancouver General
Hospital
- Richard Fluck, MD – Royal Derby
Hospital, Derby, United
Kingdom
- Sheru Kansal, MD – Cleveland
Clinic
- Paul Komenda, MD – Seven Oaks
General Hospital, Winnipeg,
Canada
- George Bakris, MD - University of Chicago Medicine
This new panel will continue to build the body of evidence to
advance adoption of therapy with the NxStage® System One™. Through
their findings, the board will seek to highlight the benefits of
HHD therapy and advance the quality of dialysis care. The group
will also advise NxStage on other focus items in its innovation
pipeline, specifically with new perspectives related to peritoneal
dialysis and alternative treatment applications.
"NxStage's selection of outstanding clinical leaders to develop
critical impactful data is a major step toward enhancing access to
this differentiated therapy option," said Dr. Collins. "NxStage is
committed to significant innovation in dialysis care, and the
impact its technologies can and will have are life-changing. It's
an honor that this prestigious group of nephrologists and cardio
renal experts from around the world has chosen to join me in this
important role. Through extensive clinical research, we expect to
demonstrate the benefits of these advancements and help to guide
further innovation needed so that we may advance patient care."
"Over the years, we've shown that HHD with the System One is not
just another home alternative, but a differentiated therapy with
clinically significant benefits," said NxStage President,
Joe Turk. "Our trusted clinician
advisors have always served a critical role in helping to define
the data we need to show and how these may be communicated to
advance therapy adoption. We thank our outgoing board for their
years of commitment, and are incredibly excited to benefit from
this new board's diverse experience and unique backgrounds in the
years to come."
To learn more about NxStage's Scientific Advisory Board members,
please visit
http://www.nxstage.com/ourcompany/scientific-advisory-board.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical
Inc. (Nasdaq: NXTM) is a medical device company, headquartered
in Lawrence, Massachusetts,
USA, that develops, manufactures and markets innovative
products for the treatment of ESRD and acute kidney failure. For
more information on NxStage and its products, please visit the
Company's website at www.nxstage.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including the Annual Report on Form 10-K for the year
ended December 31, 2014. NxStage is
under no obligation to (and expressly disclaims any such obligation
to) update or alter its forward-looking statements, whether as a
result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-establishes-new-scientific-advisory-board-to-build-clinical-evidence-and-drive-adoption-of-home-hemodialysis-therapy-300076294.html
SOURCE NxStage Medical, Inc.